|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
Injection
|
|
gptkbp:administered_once
|
Daily
|
|
gptkbp:approved_for_use
|
gptkb:FDA
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:atccode
|
A10 BH03
|
|
gptkbp:available_on
|
Pre-filled pen
|
|
gptkbp:brand
|
gptkb:Saxenda
gptkb:Victoza
|
|
gptkbp:chemical_formula
|
C172 H265 N43 O51
|
|
gptkbp:class
|
Peptide
antidiabetic agent
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
Diabetes management
Weight management
|
|
gptkbp:contraindication
|
personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Personal or family history of medullary thyroid carcinoma
|
|
gptkbp:developed_by
|
gptkb:Novo_Nordisk
|
|
gptkbp:dosage_form
|
Solution for injection
0.6 mg
|
|
gptkbp:effect_on_blood_sugar
|
Lowering blood sugar levels
|
|
gptkbp:effective_date
|
gptkb:2010
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Liraglutide
|
|
gptkbp:indication
|
Chronic weight management
Improvement of glycemic control
|
|
gptkbp:ingredients
|
gptkb:Liraglutide
|
|
gptkbp:interacts_with
|
gptkb:diabetes
gptkb:Warfarin
Sulfonylureas
other antidiabetic medications
|
|
gptkbp:invention
|
gptkb:2023
Patented
|
|
gptkbp:lifespan
|
13 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkb:Novo_Nordisk
|
|
gptkbp:mechanism_of_action
|
gptkb:SS
|
|
gptkbp:patient_population
|
Adults
Pediatric patients over 10 years old
|
|
gptkbp:requires
|
Prescription only
|
|
gptkbp:research_focus
|
Quality of life
Long-term safety
Cardiovascular outcomes
Renal outcomes
|
|
gptkbp:route_of_administration
|
Subcutaneous
subcutaneous
|
|
gptkbp:safety
|
Category C
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Vomiting
Headache
Constipation
nausea
vomiting
|
|
gptkbp:storage
|
Refrigerated
|
|
gptkbp:strength
|
Weight loss
|
|
gptkbp:trade
|
gptkb:Saxenda
gptkb:Victoza
|
|
gptkbp:used_for
|
Obesity
Type 2 diabetes
type 2 diabetes
|
|
gptkbp:weight
|
3751.6 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Ferring_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|